

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Nanjing Leads Biolabs Co., Ltd.
南京维立志博生物科技股份有限公司

(A joint stock company established in the People's Republic of China with limited liability)

(Stock Code: 9887)

**CHANGE IN COMPOSITION OF THE NOMINATION COMMITTEE
AND
APPOINTMENT OF LEAD INED**

The board (the “**Board**”) of directors (the “**Directors**”) of Nanjing Leads Biolabs Co., Ltd. (南京维立志博生物科技股份有限公司) (the “**Company**”) is pleased to announce that (i) Mr. Du Yilong (“**Mr. Du**”), an independent non-executive Director, has ceased to be a member of the nomination committee of the Company (“**Nomination Committee**”), and (ii) Ms. Du Jiliu (杜季柳) (“**Ms. Du**”), an independent non-executive Director, has been appointed as a member of the Nomination Committee with effect from the Listing Date. Unless otherwise defined herein, capitalized terms used in this announcement shall have the same meanings as those defined in the prospectus dated July 17, 2025 (the “**Prospectus**”) of the Company.

The biographical details of Ms. Du were set out in the Prospectus. As at the date of this announcement, there has been no change in such information save as disclosed in this announcement.

Following the appointment of Ms. Du, the Nomination Committee has one director of a different gender. This appointment is in response to the amended Corporate Governance Code and the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited which has come into effect on July 1, 2025. The Board believes that the implementation of this change can strengthen the effectiveness and diversity of the Nomination Committee and further enhance good corporate governance practices of the Company as a whole.

Mr. Du, currently an independent non-executive Director, a member of the audit committee and the chairperson of the remuneration committee of the Company, has been appointed as the lead independent non-executive Director of the Company (the “**Lead INED**”) for the purpose of adopting a high standard of corporate governance. The Lead INED will not have a separate or higher level of responsibility or liability relative to other INEDs on the Board. He will serve as a channel of communication to enable shareholders to understand the actions taken by INEDs in the performance of their responsibilities, as an intermediary between Directors and shareholders and enhance the communications among the INEDs and between the INEDs and the rest of the Board.

The Board would like to extend its warm welcome to Ms. Du and Mr. Du in their new roles in the Board.

By order of the Board
Nanjing Leads Biolabs Co., Ltd.
南京维立志博生物科技股份有限公司
Dr. KANG XIAOQIANG

Chairman, Executive Director and Chief Executive Officer

Hong Kong, July 25, 2025

As at the date of this announcement, the board of directors of the Company comprises: (i) Dr. Kang Xiaoqiang (Chairman of the Board), Dr. Lai Shoupeng and Mr. Zuo Honggang as executive Directors; (ii) Mr. Zhang Yincheng, Dr. Chen Renhai and Dr. Ni Jia as non-executive Directors; and (iii) Dr. Zhang Hongbing, Mr. Du Yilong and Ms. Du Jiliu as independent non-executive directors.